Loading video... Credit: Cancer Biology & Medicine Cancer cells acquire growth advantages over normal cells in myriad ways. Changes in cell programming allow these cells to grow in an uncontrolled fashion, thereby forming the cancer mass. Hepatocellular carcinoma (HCC), being highly malignant and invasive with a high recurrence rate and drug resistant phenotype, is one of the most dreadful cancers. Understanding the underlying molecular mechanisms is crucial to design therapeutic interventions and to predict patient prognosis. Cancer cells use metabolic, immunogenic, or growth-related strategies, which can be controlled by a number of alterations in the cell process. Of these, "post-transcriptional RNA modification" has recently sparked interest among cancer biologists. N6-methyladenosine (m6A) methylation, a type of RNA modification, remains the most abundant epigenetic (non-DNA related) modification in eukaryotic cells. Abnormal activity of proteins that handle m6A regulation has been linked to cancer hallmarks like invasion, metastasis, and drug resistance in several cancers including HCC. But does this correlation translate into a causative relationship? Can m6A modification influence the behavior of HCC and help predict prognosis?